Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Articles
Articles
Patient-Reported Outcomes of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone
Multiple Myeloma
2022 Year in Review - Multiple Myeloma
Results of patient-reported outcomes from the GRIFFIN study showed improved health-related quality of life in patients with NDMM with the addition of daratumumab to lenalidomide, bortezomib, and dexamethasone.
Read More
Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma with No Prior BCMA-Targeted Treatment: Results from MagnetisMM-3
Multiple Myeloma
2022 Year in Review - Multiple Myeloma
Results from cohort A of MagnetisMM-3 showed promising efficacy and a tolerable safety profile with elranatamab in RRMM patients naïve to BCMA-targeted treatment.
Read More
ALLO-715, an Allogeneic Anti-BCMA CAR T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: Results from UNIVERSAL
Multiple Myeloma
2022 Year in Review - Multiple Myeloma
Phase 1 data of ALLO-715 followed by lymphodepletion showed durable responses in heavily pretreated RRMM patients.
Read More
Teclistamab Showed Durable Responses in Heavily Pretreated Patients with Multiple Myeloma
Multiple Myeloma
2022 Year in Review - Multiple Myeloma
Phase 2 results from MajesTEC-1 showed substantial clinical activity with teclistamab and are consistent with phase 1 findings.
Read More
First-in-Human Phase 1/2 Study of REGN5458 in Heavily Pretreated Patients with Multiple Myeloma
Multiple Myeloma
2022 Year in Review - Multiple Myeloma
REGN5458, a BCMAxCD38 bispecific antibody, demonstrated early durable responses with a tolerable safety profile and low rates of CRS in patients with relapsed/refractory multiple myeloma.
Read More
Real-World Analysis of Treatment Patterns and Outcomes in Patients with MM by Cytogenetic Risk
Multiple Myeloma
2022 Year in Review - Multiple Myeloma
Real-world analysis of patients with MM determines treatment patterns and survival outcomes in patients with t(11;14) compared to patients with high- and standard-risk cytogenetics.
Read More
Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma: Phase 1/2 Results from MonumenTAL-1
Multiple Myeloma
2022 Year in Review - Multiple Myeloma
Updated phase 2 results of the MonumenTAL-1 study showed promising efficacy and a tolerable safety profile with talquetamab, a novel T-cell–redirecting bispecific antibody, in patients with RRMM.
Read More
Systematic Review and Meta-Analysis Comparing Whole-Body MRI and FDG PET/CT in Evaluating Treatment Response in Multiple Myeloma
Multiple Myeloma
2022 Year in Review - Multiple Myeloma
Meta-analysis of whole-body MRI versus FDG PET/CT to assess treatment response in MM may suggest a complementary benefit when utilizing both modalities.
Read More
Isatuximab plus Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: ICARIA-MM Final OS Analysis
Multiple Myeloma
2022 Year in Review - Multiple Myeloma
Final analysis of ICARIA-MM demonstrated a 6.9-month improvement in survival with Isa-Pd compared to Pd alone in RRMM patients.
Read More
Daratumumab plus Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: Long-Term Outcomes from MAIA
Multiple Myeloma
2022 Year in Review - Multiple Myeloma
Long-term outcomes from MAIA support the use of daratumumab plus lenalidomide and dexamethasone for ≥18 months in newly diagnosed, transplant ineligible MM patients.
Read More
Page 12 of 339
9
10
11
12
13
14
15
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Addressing Cancer Health Disparities: The No One Left Alone Initiative
Rohan Nathwani
,
Arva Patel
,
Warner Kornberg
,
Asutosh Gor, MD
,
Sashi Naidu, MD
,
Viral Rabara, MD
,
Niyati Nathwani, MD
,
Kashyap Patel, MD
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
Talvey Receives Accelerated Approval for Relapsed or Refractory Multiple Myeloma
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma